uracil has been researched along with Diabetic Angiopathies in 7 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 6.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| "The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a recent acute coronary syndrome (ACS) event, in 49 countries, to double-blind treatment with alogliptin or placebo in addition to standard of care." | 5.24 | Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Gourlie, NM; Heller, SR; Kupfer, S; Liu, Y; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2017) |
| "Treatment naïve subjects with type 2 diabetes received 12." | 2.80 | Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. ( Hirate, M; Kaneoka, N; Kutoh, E, 2015) |
| "We evaluated the incidence of CV events in patients treated with alogliptin, placebo or comparator antihyperglycaemic drugs in the clinical trial database for alogliptin using the composite major adverse cardiovascular event (MACE) endpoints of CV death, non-fatal myocardial infarction and non-fatal stroke." | 2.78 | Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. ( Fleck, P; Hisada, M; Menon, V; Munsaka, M; Pratley, R; White, WB; Wilson, C, 2013) |
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 2.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hwang, YC | 1 |
| Morrow, DA | 1 |
| Cannon, CP | 3 |
| Liu, Y | 2 |
| Bergenstal, R | 1 |
| Heller, S | 2 |
| Mehta, C | 2 |
| Cushman, W | 1 |
| Bakris, GL | 3 |
| Zannad, F | 3 |
| White, WB | 4 |
| Pratley, R | 1 |
| Fleck, P | 2 |
| Munsaka, M | 1 |
| Hisada, M | 1 |
| Wilson, C | 2 |
| Menon, V | 1 |
| Kutoh, E | 1 |
| Kaneoka, N | 1 |
| Hirate, M | 1 |
| Wang, H | 1 |
| Liu, J | 1 |
| Zhao, H | 1 |
| Heller, SR | 1 |
| Bergenstal, RM | 2 |
| Kupfer, S | 1 |
| Cushman, WC | 2 |
| Mehta, CR | 1 |
| Nissen, SE | 2 |
| Wilson, CA | 1 |
| Gourlie, NM | 1 |
| Davidson, EP | 1 |
| Coppey, LJ | 1 |
| Dake, B | 1 |
| Yorek, MA | 1 |
| Perez, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
1 review available for uracil and Diabetic Angiopathies
| Article | Year |
|---|---|
Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin.
Topics: Animals; Arteries; Asian People; China; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl | 2015 |
5 trials available for uracil and Diabetic Angiopathies
1 other study available for uracil and Diabetic Angiopathies
| Article | Year |
|---|---|
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopa | 2011 |